Border Bio specializes in providing consulting services to emerging companies ready to move their drug candidates into advanced preclinical development toward the clinic or into early-phase clinical trials with an emphasis on complex therapeutics including biologics and cell and gene therapies. We are experts in helping small companies achieve first-in-human studies rapidly and economically.

Our services include regulatory guidance and assistance with the planning and execution of nonclinical and clinical studies and manufacturing development. Our team has helped companies successfully advance seven different innovative therapy candidates from lead identification to first-in-human studies in less than 14 months for less than $2 million each. Contact us about how we can help you with your innovative technology.

We also specialize in helping small biotech companies compete for and prepare to manage Federal research contracts for countermeasure development addressing public health emergency responses. Contact us if you are thinking about crossing that border.